Andy,
Got to agree heavily here.
Sox we know the board are targeting 4mtpa.
Let me just lightly gloss over what that means for 1 years production ONLY, and ONLY on a spodumene operation, which has the lesser margin when compared to a carbonate/hydroxide operation which is the end game.
4mtpa = 780,000t spodumene at 6%
300 cash cost vs $1,000 USD sales price = 700m USD margin per tonne.
1 years operation = 546,000,000m USD cash profit.
In AUD that's $728,000,000...
Il let that sit in silence......
So whilst a pause is taken for that, apply a PE of 7 which is light on for a LOM of 20 in a bull market, and that's effectively 5 billion.
Divide that by 235m shares... that's $21 a share...
Now assume, say an RG outcome where 40/40/20 split with some JV partner and Mali Gov as a template and you get $8 per share....
$8 per share vs 50c
Conservative cash cost, conservative sales price, conservative operation (only spod not higher margin carbonate/hydroxide), conservative PE...
We really need to be talking multi dollars here.... that's why I heavily agree with your graph.
Spot on.
- Forums
- ASX - By Stock
- FFX
- Possible Potential in two to three years.
Possible Potential in two to three years., page-99
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online